All In Biotech

Drug Trial Radar · NCT05419180

Study of Interest of Stiripentol and Carbamazepine in the Treatment of Patients With Pharmacoresistant Focal Epilepsies

Study of the Interest of the Combination of Stiripentol (Diacomit®) and Carbamazepine in the Treatment of Patients With Pharmacoresistant Focal Epilepsies

Last checked: Nov 19, 2026Latest source record: Jul 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Actual

Start

Oct 13, 2022

Primary completion

Jun 13, 2024

Study completion Jun 13, 2024

Sponsor

Lead sponsor
BiocodexIndustry
Sponsor type
Industry
First posted
Jun 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a monocentric, open-label clinical study, presenting a retrospective part and a prospective part, studying the data of patients with drug-resistant focal epilepsies and treated with the combination of stiripentol (Diacomit®) and Carbamazepine.

Conditions

  • Pharmacoresistant Focal Epilepsies

Interventions

  • StiripentolDrug

    Since the treatment usually received by patients should not be modified, the sponsor will not intervene in any way in the therapeutic management of patients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AgeTime frame: through study completion, an average of 1 year
  2. Previous antiepileptic treatments receivedTime frame: through study completion, an average of 1 year
  3. SurgeryTime frame: through study completion, an average of 1 year
  4. Adjustment of carbamazepine treatment over the timeTime frame: through study completion, an average of 1 year
  5. Adjustment of stiripentol treatment over the timeTime frame: through study completion, an average of 1 year
  6. Adjustment of concomitant treatments over the timeTime frame: through study completion, an average of 1 year
  7. monthly seizures over the timeTime frame: through study completion, an average of 1 year
  8. status epilepticus in the pastTime frame: through study completion, an average of 1 year
  9. duration of the status epileticus over the timeTime frame: through study completion, an average of 1 year
  10. emergency room consultation and/or hospitalization over the timeTime frame: through study completion, an average of 1 year
  11. emergency antiepileptic treatment over the timeTime frame: through study completion, an average of 1 year
  12. frequency of the status epileticus over the timeTime frame: through study completion, an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre de Référence Epilepsies Rares / Centre Investigation Clinique (CIC) - Hôpital Necker-Enfants Malades

    Paris, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.